Trending stocks today
Amgen Inc. (AMGN-Q)
NASDAQ:AMGN
294.02
0.77
(0.26%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
Related posts
Shopify leads TSX to 25,000, Wall St. fadesSoft jobs report lifts U.S. markets, TSX flatStocks flat, Bitcoin risesThis summary was created by AI, based on 20 opinions in the last 12 months.
Amgen Inc. (AMGN) is gaining attention as a solid investment within the bio-pharma sector, particularly due to its diverse portfolio and competitive valuation compared to peers like LLY and NVO. Analysts highlight its attractive P/E ratio of around 14-15 times earnings, which is significantly lower than that of LLY, suggesting better value for potential investors. The company continues to generate consistent earnings and free cash flow, reflected in its dividend yield of around 3.2-3.65%, making it a reliable dividend play for long-term growth. Experts express optimism about Amgen's existing drugs, particularly Repatha, while acknowledging concerns about its weight-loss drug, which is currently in phase 2 trials but could be positioned for substantial revenue growth if successful. Overall, analysts maintain a positive outlook on Amgen's future growth potential, especially following its acquisition of Horizon Therapeutics, which is expected to bolster its growth trajectory.
$288.990
Owned
Diversity is good in the bio pharma space. It is a fully diversified large cap and he would have it as a core holding.
A dividend play for 2025 at 3.65%. Not sexy, but consistently generates earnings, free cash flow, and each year grows its dividend. Offers growth wealth generation over time.
He still believes in their key drug, Repatha. His concern lies with their weight-loss drug and their disappointing results.
Today's downgraded doesn't bother him. These calls go back and forth often. Their weight-loss drug could add $10 billion revenues. A good time to own this.
They just bought Horizon Therapeutics, a growth engine, and have a weight-loss drug in phase 2 trials that is promising facing a huge market. They trade at a decent PE and enjoy good growth from their core drugs.
He prefers Amgen, because their weight-loss drug is under trial and not priced into the stock yet. And it trades at a lower PE than these peers.
Trades at a healthy 15x earnings and 66% gross margin (56% in the sector). It pays a 3% dividend. They just bought Horizon Therapeutics which adds growth. Their early-stage obesity drug shows great promise in a $100 billion potential market.
(Analysts’ price target is $319.54)Owns this instead of NVO. A much less troublesome valuation. Also has a weight-loss drug in trial. You want to be in before the good news, not after.
Our PAST TOP PICK with AMGN has achieved its target at $319. To remain disciplined, we recommend covering half the position at this time and trailing up the stop (from $210) to $260.
He's surprised with how strongly shares are soaring on phase 3 trial results of their obesity drug. They're a little late to the party in these drugs, but theirs you would take less often their than peers'. Also, a recent acquisition makes them double-digit revenue growers and is accretive. Loves the dividend growth too.
Legacy products that continue to do well. But new products are contributing well, too. Latest acquisition adding significantly to growth profile. Reasonable multiple of 12-13x, good prospects for growth. Out of favour, along with many healthcare stocks. Good, long-term hold.
Pays a 3.2% dividend and trades at a 14x forward PE.
Amgen Inc.(AMGN-Q) Rating
Ranking : 5 out of 5
Bullish - Buy Signals / Votes : 16
Neutral - Hold Signals / Votes : 2
Bearish - Sell Signals / Votes : 1
Total Signals / Votes : 19
Amgen Inc.(AMGN-Q) Frequently Asked Questions
What is Amgen Inc. stock symbol?
Amgen Inc. is a American stock, trading under the symbol AMGN-Q on the NASDAQ (AMGN). It is usually referred to as NASDAQ:AMGN or AMGN-Q
Is Amgen Inc. a buy or a sell?
In the last year, 19 stock analysts published opinions about AMGN-Q. 16 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Amgen Inc..
Is Amgen Inc. a good investment or a top pick?
Amgen Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Amgen Inc..
Why is Amgen Inc. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Amgen Inc. worth watching?
19 stock analysts on Stockchase covered Amgen Inc. In the last year. It is a trending stock that is worth watching.
What is Amgen Inc. stock price?
On 2025-02-11, Amgen Inc. (AMGN-Q) stock closed at a price of $294.02.
Phase 2 drug in the GLP-1 space -- not as mature as LLY's drug, but you don't pay as much for this company either. Trades ~14x earnings, compared to 50x for LLY. And that's more his style of investing.